{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:22Z","timestamp":1792783102230,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005941","name":"Dietmar Hopp Stiftung","doi-asserted-by":"publisher","award":["23011211"],"award-info":[{"award-number":["23011211"]}],"id":[{"id":"10.13039\/501100005941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004937","name":"Bundesministerium f\u00fcr Forschung und Technologie","doi-asserted-by":"publisher","award":["FKZ 01GI1602D"],"award-info":[{"award-number":["FKZ 01GI1602D"]}],"id":[{"id":"10.13039\/501100004937","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P32699"],"award-info":[{"award-number":["P32699"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2067\/1- 390729940"],"award-info":[{"award-number":["EXC 2067\/1- 390729940"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003493","name":"Gemeinn\u00fctzige Hertie-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003493","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsche Multiple Sklerose Gesellschaft","id":[{"id":"https:\/\/ror.org\/05w9xct02","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001661","name":"Ruprecht-Karls-Universit\u00e4t Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00401-020-02236-5","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T12:06:06Z","timestamp":1603109166000},"page":"127-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis"],"prefix":"10.1007","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-3338","authenticated-orcid":false,"given":"Brigitte","family":"Wildemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Jarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stadelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"2236_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","volume":"264","author":"A Cobo-Calvo","year":"2017","unstructured":"Cobo-Calvo A, Ruiz A, D'Indy H, Poulat AL, Carneiro M, Philippe N et al (2017) MOG antibody-related disorders: common features and uncommon presentations. J Neurol 264:1945\u20131955","journal-title":"J Neurol"},{"key":"2236_CR2","doi-asserted-by":"publisher","first-page":"eaam7816","DOI":"10.1126\/scitranslmed.aam7816","volume":"9","author":"MK Fard","year":"2017","unstructured":"Fard MK, van der Meer F, Sanchez P, Cantuti-Castelvetri L, Mandad S, Jakel S et al (2017) BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. Sci Transl Med 9:eaamm7816","journal-title":"Sci Transl Med"},{"key":"2236_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10024-0","author":"M Gastaldi","year":"2020","unstructured":"Gastaldi M, Scaranzin S, Jarius S, Wildeman B, Zardini E, Mallucci G et al (2020) Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10024-0","journal-title":"J Neurol"},{"key":"2236_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement: frequency, presentation and outcome. J Neuroinflammation 13:281","journal-title":"J Neuroinflammation"},{"key":"2236_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134","journal-title":"J Neuroinflammation"},{"key":"2236_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13:280","journal-title":"J Neuroinflammation"},{"key":"2236_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13:279","journal-title":"J Neuroinflammation"},{"key":"2236_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","volume":"17","author":"S Jarius","year":"2020","unstructured":"Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hummert MW, Ringelstein M et al (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 17:261","journal-title":"J Neuroinflammation"},{"key":"2236_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14","journal-title":"J Neuroinflammation"},{"key":"2236_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184","journal-title":"J Neuroinflammation"},{"key":"2236_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 13:282","journal-title":"J Neuroinflammation"},{"key":"2236_CR12","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1352458517731914","volume":"24","author":"M Sepulveda","year":"2018","unstructured":"Sepulveda M, Sola-Valls N, Escudero D, Rojc B, Baron M, Hernandez-Echebarria L et al (2018) Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler 24:1753\u20131759","journal-title":"Mult Scler"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-020-02236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-020-02236-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-020-02236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T01:56:23Z","timestamp":1634608583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-020-02236-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1007\/s00401-020-02236-5","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Brigitte Wildemann received grants from German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation, and Klaus Tschira Foundation, grants and personal fees from Merck Serono, Sanofi Genzyme, and Novartis pharmaceuticals, and personal fees from Bayer Healthcare, Biogen, Teva Pharma. Sven Jarius reports no conflicts of interest. Jonas Franz reports no conflicts of interest. Klemens Ruprecht received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charit\u00e9 (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received speaker honoraria and travel grants from Bayer, Biogen Idec, Merck Serono, sanofi-aventis\/Genzyme, Teva, Roche, Novartis, and Guthy Jackson Charitable Foundation. Markus Reindl reports the following conflicts of interest: The University Hospital and Medical\u00a0University of Innsbruck (Austria; employer of\u00a0MR) receives payments for antibody assays\u00a0(MOG, AQP4 and other autoantibodies) and for\u00a0MOG and AQP4 antibody validation experiments\u00a0organized by Euroimmun (L\u00fcbeck, Germany). Markus Reindl is supported by a research grant from the Austrian Science Fund (FWF, project\u00a0P32699). Christine Stadelmann has received research support from Novartis and Medday, speaker\u2019s honoraria from Novartis and Roche and served on advisory boards of Merck Serono and Roche. No conflicts of interests with regard to the present work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The patient has given written consent to the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}